According to The Detroit News, 246 “breakthrough cases” were reported between Jan. 1 and March 31. All cases occurred in people who tested positive 14 or more days after the last dose in the vaccine series, said Lynn Sutfin, spokeswoman for the Michigan Department of Health and Human Services, in an email.
“Some of these individuals may ultimately be excluded from this list due to continuing to test positive from a recent infection prior to being fully vaccinated,” she said. But these “cases are undergoing further review to determine if they meet other [Centers for Disease Control and Prevention] CDC criteria for determination of potential breakthrough, including the absence of a positive antigen or PCR test less than 45 days prior to the post-vaccination positive test.”
Sutfin said these persons were more likely to be asymptomatic or mildly symptomatic, adding that hospitalization data were available for 117 of the cases, while 129 were incomplete.
Of the 117 with hospitalization data entered, 11 were hospitalized, 103 were not hospitalized and three are reported as unknown. The three people who died were all 65 or older and two “were within three weeks of completion of vaccination,” Sutfin said.
According to Dr. Nick Gilpin, Beaumont’s medical director for infection prevention, eight patients who had been “fully vaccinated” were being treated for COVID at Beaumont Health’s hospitals on Monday.
“While the majority of the population develops full immunity within 14 days of completion of their vaccine series, a small proportion appear to take longer to mount a full antibody response,” Sutfin explained. “The CDC is actively working to better understand the risk characteristics of this group.”
As The Defender reported April 5, scientists have challenged health officials on vaccinating people who’ve already had COVID, arguing the science supporting vaccination of those primed with COVID doesn’t exist and there’s a potential risk of harm, including death, in vaccinating those who’ve already had the disease or were recently infected.
Dr. Hooman Noorchashm, surgeon and patient safety advocate, has written several letters to the U.S. Food and Drug Administration urging the agency to require pre-screening for SARS-CoV-2 viral proteins — which would be present in someone who has already been infected with COVID — in an effort to reduce COVID vaccine injuries and deaths.
According to Noorchasm, it is scientifically established that once a person is naturally infected by a virus, antigens from that virus persist in the body for a long time after viral replication has stopped and clinical signs of infection have resolved. When a vaccine reactivates an immune response in a recently infected person, the tissues harboring the persisting viral antigen are targeted, inflamed and damaged by the immune response.
“In the case of SARS-CoV-2, we know that the virus naturally infects the heart, the inner lining of blood vessels, the lungs and the brain,” explained Noorchasm. “So, these are likely to be some of the critical organs that will contain persistent viral antigens in the recently infected — and, following reactivation of the immune system by a vaccine, these tissues can be expected to be targeted and damaged.”
J. Patrick Whelan M.D., Ph.D., expressed similar concern that COVID vaccines aimed at creating immunity against the SARS-CoV-2 spike protein could have the potential to cause microvascular injury to the brain, heart, liver and kidneys in a way that does not currently appear to be assessed in safety trials of these potential drugs.
As The Defender reported March 31, Washington, Florida, South Carolina, Texas, New York, California and Minnesota have all reported breakthrough cases of COVID, and two deaths are under investigation by the Department of Health in Washington.